Hinge Health director-linked funds sell stock around $92

Q: What insider transactions were reported for HNGE by director Robinson Elliott?

The filing reports two indirect sale transactions of Hinge Health Class A Common Stock tied to Bessemer venture funds on September 4, 2026 and September 8, 2026, with specific share counts and weighted average prices disclosed in footnotes.

Q: How many HNGE shares did the Bessemer funds sell on September 4, 2026?

On September 4, 2026, Bessemer Venture Partners X L.P. sold 7,450 shares and Bessemer Venture Partners X Institutional L.P. sold 6,994 shares of Hinge Health Class A Common Stock at a weighted average price of $92.17.

Q: How many HNGE shares did the Bessemer funds sell on September 8, 2026?

On September 8, 2026, Bessemer Venture Partners X L.P. sold 21,006 shares and Bessemer Venture Partners X Institutional L.P. sold 19,719 shares of Hinge Health Class A Common Stock at a weighted average price of $92.58.

Q: What price ranges were HNGE shares sold at in these transactions?

For the September 4, 2026 sales, shares were sold at prices ranging from $92.00 to $92.73. For the September 8, 2026 sales, shares were sold at prices ranging from $92.00 to $93.00, with weighted average prices reported for each date.

Q: Does Robinson Elliott claim beneficial ownership of the HNGE shares sold?

The filing states that Robinson Elliott has an indirect, passive economic interest in the Bessemer funds and disclaims beneficial ownership of their Hinge Health securities, except to the extent of his pecuniary interest, if any, through those indirect interests.

Q: Were the reported HNGE sales made under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not checked, and the footnotes do not state that the transactions were made under a Rule 10b5-1 trading plan, so no Rule 10b5-1 plan is reported for these sales.

Director Robinson Elliott reported indirect sales in HNGE shares by Bessemer venture funds, while disclaiming beneficial ownership except for any indirect pecuniary interest.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Hinge Health, Inc. (HNGE) director Robinson Elliott reported two indirect sales of Class A Common Stock associated with Bessemer venture funds. On September 4, 2026, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. sold 7,450 and 6,994 shares, respectively, at a weighted average price of $92.17. On September 8, 2026, the same funds sold 21,006 and 19,719 shares, respectively, at a weighted average price of $92.58. The shares were sold in multiple transactions within disclosed price ranges, and Elliott disclaims beneficial ownership except for any indirect pecuniary interest.

Insider Trade Summary

Sale: 0 shares

Sale 2 txns

Insider Robinson Elliott

Role Director

Sold 0 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock ^{F2, F3}	0	$0.00	$0.00
Sale	Class A Common Stock ^{F1, F3}	0	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 0 shares (Indirect, See footnote)

Footnotes (3)

F1. On September 4, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 7,450 and 6,994 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.17. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.73. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2. On September 8, 2026, BVP X and BVP X Inst sold 21,006 and 19,719 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.58. These shares were sold in multiple transactions at prices ranging from $92.00 to $93.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

Key Figures

Shares sold September 4, 2026 (BVP X): 7,450 shares Shares sold September 4, 2026 (BVP X Inst): 6,994 shares Weighted average price September 4, 2026: $92.17 per share +5 more

8 metrics

Shares sold September 4, 2026 (BVP X) 7,450 shares Class A Common Stock sold by Bessemer Venture Partners X L.P. at weighted average price

Shares sold September 4, 2026 (BVP X Inst) 6,994 shares Class A Common Stock sold by Bessemer Venture Partners X Institutional L.P. at weighted average price

Weighted average price September 4, 2026 $92.17 per share Sales of Hinge Health Class A Common Stock by the Bessemer Funds

Price range September 4, 2026 $92.00–$92.73 per share Multiple transactions making up the September 4, 2026 sales

Shares sold September 8, 2026 (BVP X) 21,006 shares Class A Common Stock sold by Bessemer Venture Partners X L.P. at weighted average price

Shares sold September 8, 2026 (BVP X Inst) 19,719 shares Class A Common Stock sold by Bessemer Venture Partners X Institutional L.P. at weighted average price

Weighted average price September 8, 2026 $92.58 per share Sales of Hinge Health Class A Common Stock by the Bessemer Funds

Price range September 8, 2026 $92.00–$93.00 per share Multiple transactions making up the September 8, 2026 sales

Key Terms

weighted average price, indirect, passive economic interest, pecuniary interest, beneficial ownership

4 terms

weighted average price financial

"sold ... shares ... at a weighted average price of $92.17"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect, passive economic interest financial

"has an indirect, passive economic interest in the shares held"

pecuniary interest financial

"except to the extent of his pecuniary interest, if any"

beneficial ownership regulatory

"disclaims beneficial ownership of the securities held by the Bessemer Funds"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What insider transactions were reported for HNGE by director Robinson Elliott?

The filing reports two indirect sale transactions of Hinge Health Class A Common Stock tied to Bessemer venture funds on September 4, 2026 and September 8, 2026, with specific share counts and weighted average prices disclosed in footnotes.

How many HNGE shares did the Bessemer funds sell on September 4, 2026?

On September 4, 2026, Bessemer Venture Partners X L.P. sold 7,450 shares and Bessemer Venture Partners X Institutional L.P. sold 6,994 shares of Hinge Health Class A Common Stock at a weighted average price of $92.17.

How many HNGE shares did the Bessemer funds sell on September 8, 2026?

On September 8, 2026, Bessemer Venture Partners X L.P. sold 21,006 shares and Bessemer Venture Partners X Institutional L.P. sold 19,719 shares of Hinge Health Class A Common Stock at a weighted average price of $92.58.

What price ranges were HNGE shares sold at in these transactions?

For the September 4, 2026 sales, shares were sold at prices ranging from $92.00 to $92.73. For the September 8, 2026 sales, shares were sold at prices ranging from $92.00 to $93.00, with weighted average prices reported for each date.

Does Robinson Elliott claim beneficial ownership of the HNGE shares sold?

The filing states that Robinson Elliott has an indirect, passive economic interest in the Bessemer funds and disclaims beneficial ownership of their Hinge Health securities, except to the extent of his pecuniary interest, if any, through those indirect interests.

Were the reported HNGE sales made under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not checked, and the footnotes do not state that the transactions were made under a Rule 10b5-1 trading plan, so no Rule 10b5-1 plan is reported for these sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/09/2026 - 05:51 PM Accepted by SEC EDGAR 09/09/2026 - 05:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson Elliott

(Last)

(First)

(Middle)

C/O BESSEMER VENTURE PARTNERS

1865 PALMER AVENUE, SUITE 104

(Street)

LARCHMONT

NEW YORK

10538

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	09/04/2026		S		0⁽¹⁾	D	$0	0	I	See footnote⁽¹⁾⁽³⁾
Class A Common Stock	09/08/2026		S		0⁽²⁾	D	$0	0	I	See footnote⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On September 4, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 7,450 and 6,994 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.17. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.73. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. On September 8, 2026, BVP X and BVP X Inst sold 21,006 and 19,719 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $92.58. These shares were sold in multiple transactions at prices ranging from $92.00 to $93.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

	/s/ Augie Wilkinson, Attorney-in-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Hinge Health director-linked funds sell stock around $92

Rhea-AI Filing Summary

Positive

Negative